Recent advancements in cervical cancer screening have prompted updated guidelines aimed at improving early detection and reducing mortality from the disease, which continues to claim over 250,000 lives worldwide annually, including approximately 4,000 in the United States.

Cervical cancer is largely preventable through regular screening and vaccination against human papillomavirus (HPV), the primary cause of most cervical precancerous lesions. Traditionally, screening has relied on the Pap smear, or cervical cytology, which involves collecting cells from the cervix for laboratory examination. However, as the link between persistent HPV infection and cervical cancer became clearer, testing for HPV itself has become an increasingly important tool in identifying individuals at risk.

Newly approved in 2024, self-collection kits for HPV testing can be used in clinical settings, with home use authorized in 2025. These kits allow samples to be taken vaginally by the patient rather than requiring a clinician-collected cervical sample. Studies indicate that self-collected samples have accuracy comparable to clinician-collected tests, potentially lowering barriers to screening, especially for patients who find pelvic exams uncomfortable or invasive.

Screening recommendations differ by age and governing medical bodies. For those aged 30 and older at average risk, there is broad consensus that HPV testing is preferable due to its earlier identification of risk and lower false positive rates. For individuals in their 20s, guidelines diverge. The American College of Obstetricians and Gynecologists (ACOG) and the Women’s Preventive Services Initiative (WPSI) recommend continued use of cytology from ages 21 to 29, citing the prevalence of transient HPV infections in younger patients that often resolve without intervention. Conversely, the American Cancer Society advises HPV testing beginning at age 25, emphasizing earlier detection.

All major organizations approve HPV self-collection as an option, though ACOG and the American Cancer Society express preference for clinician-collected samples where feasible. Follow-up testing is required for positive HPV results, and clinician-collected samples can be retested directly, whereas self-collected vaginal samples require patients to return for additional procedures, which may impact adherence and outcomes.

Screening intervals vary slightly: ACOG recommends cytology every three years for ages 21 to 29, and HPV testing every five years for ages 30 to 65. For individuals who opt for self-collection, screenings are advised every three years due to limited long-term data. The WPSI aligns closely with these timelines, while the American Cancer Society recommends HPV testing every five years starting at age 25, with self-collected tests every three years as an alternative. These guidelines apply to average-risk patients with normal results; those at higher risk or with abnormal findings may require more frequent screenings.

Regarding the cessation of screening, experts generally agree it is safe to stop after age 65 if recent tests have been consistently normal. The number and type of normal tests required before stopping vary among guidelines, but the risk of developing cervical cancer later in life is considered low enough to justify discontinuation. Practitioners advise preparing for possible increased discomfort due to vaginal tissue changes in older age and encourage proactive testing in the years preceding the end of routine screening.

As testing options expand and evolve, healthcare providers emphasize that engaging in any recommended form of cervical cancer screening remains crucial. Proper follow-up after a positive HPV test, regardless of sample collection method, is essential to ensuring effective prevention and early treatment.